News and Trends 3 Apr 2020
Lilly Partners UK Immunometabolism Biotech in Deal Worth €811M
Eli Lilly will partner Oxford-based Sitryx to develop up to four drug candidates to treat autoimmune disease in a deal worth €811M if development milestones are met. The UK biotech will receive an upfront payment of €46M from the US big pharma, which will also buy €10M of equity in the company. Sitryx can also […]